Vertex Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Vertex Pharmaceuticals has a total shareholder equity of $17.6B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.7B and $5.1B respectively. Vertex Pharmaceuticals's EBIT is $4.3B making its interest coverage ratio -7.5. It has cash and short-term investments of $11.2B.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -7.5x |
| Cash | US$11.22b |
| Equity | US$17.58b |
| Total liabilities | US$5.15b |
| Total assets | US$22.73b |
Recent financial health updates
No updates
Recent updates
Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05
Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?
Oct 24Vertex to advance two AAT correctors to potentially treat rare, genetic disease
Oct 11Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?
Oct 02Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
Sep 28Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
Sep 19Vertex wins FDA label expansion for cystic fibrosis drug to add younger children
Sep 02Financial Position Analysis
Short Term Liabilities: VRTX's short term assets ($14.1B) exceed its short term liabilities ($3.5B).
Long Term Liabilities: VRTX's short term assets ($14.1B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: VRTX is debt free.
Reducing Debt: VRTX had no debt 5 years ago.
Debt Coverage: VRTX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VRTX has no debt, therefore coverage of interest payments is not a concern.